MItral Regurgitation Risk Assessment and CLinical modElling

Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation. MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic/diastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.

NCT Number	NCT06876883
Lead Sponsor	Sun Yat-sen University
Conditions	Mitral Insufficiency, Mitral Regurgitation (MR)
Enrollment	2,000 participants
Start Date	2016-06-15
Primary Completion	2030-06-15 (estimated)
Study Completion	2030-06-15 (estimated)
Updated on ClinicalTrials.gov	2025-09-05